154 related articles for article (PubMed ID: 23110309)
61. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
Zenz T; Vollmer D; Trbusek M; Smardova J; Benner A; Soussi T; Helfrich H; Heuberger M; Hoth P; Fuge M; Denzel T; Häbe S; Malcikova J; Kuglik P; Truong S; Patten N; Wu L; Oscier D; Ibbotson R; Gardiner A; Tracy I; Lin K; Pettitt A; Pospisilova S; Mayer J; Hallek M; Döhner H; Stilgenbauer S;
Leukemia; 2010 Dec; 24(12):2072-9. PubMed ID: 20861914
[TBL] [Abstract][Full Text] [Related]
62. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia
Davids MS; Kim HT; Yu L; De Maeyer G; McDonough M; Vartanov AR; Langey R; Fernandes SM; Hellman JM; Francoeur K; Arnason J; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR
Leuk Lymphoma; 2019 May; 60(5):1312-1315. PubMed ID: 30322319
[TBL] [Abstract][Full Text] [Related]
63. [Some genomic aberrations in B-cell chronic lymphocytic leukemia and their clinical relevance. Part I. B-cell lymphocytic leukemia with TP53 gene deletion].
Koczkodaj D; Rupniewska ZM; Wasik-Szczepanek E; Bojarska-Junak A
Pol Arch Med Wewn; 2003 Dec; 110(6):1395-403. PubMed ID: 15052934
[TBL] [Abstract][Full Text] [Related]
64. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
Monti P; Lionetti M; De Luca G; Menichini P; Recchia AG; Matis S; Colombo M; Fabris S; Speciale A; Barbieri M; Gentile M; Zupo S; Dono M; Ibatici A; Neri A; Ferrarini M; Fais F; Fronza G; Cutrona G; Morabito F
Sci Rep; 2020 Oct; 10(1):18427. PubMed ID: 33116240
[TBL] [Abstract][Full Text] [Related]
65. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
66. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
67. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
Do C; Best OG; Thurgood L; Hotinski A; Apostolou S; Mulligan SP; Lower K; Kuss B
Br J Haematol; 2021 May; 193(3):556-560. PubMed ID: 33851417
[TBL] [Abstract][Full Text] [Related]
68. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
[TBL] [Abstract][Full Text] [Related]
69. p53 protein expression in chronic lymphocytic leukemia.
Sellmann L; Carpinteiro A; Nückel H; Scholtysik R; Siemer D; Klein-Hipass L; Kube D; Dürig J; Dührsen U; Stanelle J; Küppers R
Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854
[TBL] [Abstract][Full Text] [Related]
70. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
71. What is the best frontline therapy for patients with CLL and 17p deletion?
Badoux XC; Keating MJ; Wierda WG
Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
[TBL] [Abstract][Full Text] [Related]
72. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
Dijkstra MK; van Lom K; Tielemans D; Elstrodt F; Langerak AW; van 't Veer MB; Jongen-Lavrencic M
Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
[No Abstract] [Full Text] [Related]
73. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.
de Viron E; Michaux L; Put N; Bontemps F; Van Den Neste E
Leuk Lymphoma; 2012 Aug; 53(8):1445-51. PubMed ID: 22280536
[TBL] [Abstract][Full Text] [Related]
74. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
[TBL] [Abstract][Full Text] [Related]
75.
Bomben R; Zucchetto A; Gentile M; Gattei V
Clin Cancer Res; 2021 Aug; 27(16):4462-4464. PubMed ID: 34127506
[TBL] [Abstract][Full Text] [Related]
76. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
Collado R; Puiggros A; López-Guerrero JA; Calasanz MJ; Larráyoz MJ; Ivars D; García-Casado Z; Abella E; Orero MT; Talavera E; Oliveira AC; Hernández-Rivas JM; Hernández-Sánchez M; Luño E; Valiente A; Grau J; Portal I; Gardella S; Salgado AC; Giménez MT; Ardanaz MT; Campeny A; Hernández JJ; Álvarez S; Espinet B; Carbonell F
Cancer Lett; 2017 Nov; 409():42-48. PubMed ID: 28888994
[TBL] [Abstract][Full Text] [Related]
77. Targeting p53 in chronic lymphocytic leukemia.
Moia R; Boggione P; Mahmoud AM; Kodipad AA; Adhinaveni R; Sagiraju S; Patriarca A; Gaidano G
Expert Opin Ther Targets; 2020 Dec; 24(12):1239-1250. PubMed ID: 33016796
[TBL] [Abstract][Full Text] [Related]
78. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
Marinelli M; Raponi S; Del Giudice I; De Propris MS; Nanni M; Intoppa S; Milani ML; Mauro FR; Guarini A; Foà R
Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142
[No Abstract] [Full Text] [Related]
79. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
[TBL] [Abstract][Full Text] [Related]
80. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Atherton M; Pearson K; Douglas A; Burford A; Brito-Babapulle V; Matutes E; Catovsky D; Pettitt AR
Leukemia; 2006 Apr; 20(4):737-40. PubMed ID: 16437137
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
